信达生物(01801)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01801 信达生物

已收盘 05-28 16:08:31

74.850

-4.100

-5.19%

最高79.700	最低74.600	成交量2,186万
今开78.950	昨收78.950	日振幅6.46%
总市值1,301亿	流通市值1,301亿	总股本17.38亿
成交额16.68亿	换手率1.26%	流通股本17.38亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01801","market":"HK","secType":"STK","nameCN":"信达生物","latestPrice":74.85,"timestamp":1779955711005,"preClose":78.95,"halted":0,"volume":21861582,"delay":0,"changeRate":-0.05193160227992411,"floatShares":1738000000,"shares":1738000000,"eps":0.5430593112716107,"marketStatus":"已收盘","change":-4.1,"latestTime":"05-28 16:08:31","open":78.95,"high":79.7,"low":74.6,"amount":1668072281,"amplitude":0.064598,"askPrice":74.85,"askSize":21500,"bidPrice":74.8,"bidSize":24500,"shortable":3,"etf":0,"ttmEps":0.5430593112716107,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1780018200000},"marketStatusCode":5,"adr":0,"listingDate":1540915200000,"exchange":"SEHK","adjPreClose":78.95,"openAndCloseTimeList":[[1779931800000,1779940800000],[1779944400000,1779955200000]],"volumeRatio":1.835954,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"INB.HK","impliedVol":0.4854,"impliedVolPercentile":0.3618},"requestUrl":"/m/hq/s/01801","defaultTab":"news","newsList":[{"id":"1142738745","title":"异动解读 | 信达生物盘中大跌5%，生物科技板块走弱叠加资金使用争议发酵","url":"https://stock-news.laohu8.com/highlight/detail?id=1142738745","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1142738745?lang=zh_cn&edition=full","pubTime":"2026-05-28 15:21","pubTimestamp":1779952878,"startTime":"0","endTime":"0","summary":"信达生物今日盘中大跌5%，引发市场关注。消息面上，生物科技板块今日集体走弱，康方生物、百济神州、荣昌生物、三生制药等同行股价均出现不同程度下跌，板块系统性抛压显著。此外，公司此前公告购买及认购摩根大通与瑞银投资票据合计6.9亿美元，市场对公司将大额资金用于理财而非回购进行市值管理存在争议，叠加5月中旬CEO减持事件余波，资金情绪偏弱持续压制股价。信达生物制药是一家主要从事研发、生产及销售治疗肿瘤、心血管及代谢、自身免疫及眼科等重大疾病创新药物的投资控股公司。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["01801"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638166837","title":"港股异动 | 创新药概念股集体走低 加息预期压制行业估值及投融资环境 市场关注ASCO会议进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2638166837","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638166837?lang=zh_cn&edition=full","pubTime":"2026-05-28 15:09","pubTimestamp":1779952150,"startTime":"0","endTime":"0","summary":"创新药、CXO 等成长赛道对流动性较为敏感，若美联储降息周期延后，或国内降准降息落地不及预期，市场流动性收紧将直接压制成长赛道估值。值得注意的是，2026年美国临床肿瘤学会年会将于5月29日至6月2日在美国芝加哥举行。本届ASCO共63项研究入选LBA，其中12家企业的13项研究来自中国，创历史新高；同时，94项中国研究入选口头汇报，数量近三年快速增长。上海证券指出，中国药企在国际平台彰显实力，中国创新药全球话语权逐年提升。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1447074.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","HK0000165453.HKD","159992","BK1589","BK1574","LU0502904849.HKD","01177","LU2097828557.USD","LU2097828714.EUR","LU2097828474.EUR","LU2097828631.EUR","01801","LU2242644610.SGD","IE00BZ08YR35.GBP","BK1515","BK1521","LU0455707207.USD","BK1191","06978","BK4585","BK1587","00013","IE00BZ08YT58.USD","VXUS","IE00BZ08YS42.EUR","BK4588","LU2488822045.USD","BK1161","LU2328871848.SGD","LU1969619763.USD","LU2097828805.USD","03692","BK1588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177877772","title":"异动解读｜信达生物盘中下跌3.17%，生物科技板块集体走弱叠加资金使用争议发酵","url":"https://stock-news.laohu8.com/highlight/detail?id=1177877772","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1177877772?lang=zh_cn&edition=full","pubTime":"2026-05-28 13:13","pubTimestamp":1779945202,"startTime":"0","endTime":"0","summary":"5月28日，信达生物盘中下跌3.17%，报76.45港元/股，成交额6.27亿港元。消息面上，生物科技板块今日集体走弱，康方生物跌3.99%、百济神州跌3.54%、荣昌生物跌4.25%、三生制药跌6.65%，板块系统性抛压显著。此外，公司此前公告购买及认购摩根大通与瑞银投资票据合计6.9亿美元，市场对公司将大额资金用于理财而非回购进行市值管理存在争议，叠加5月中旬CEO减持事件余波，资金情绪偏弱持续压制股价。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01801"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638150420","title":"贝莱德增持信达生物(01801)约36.95万股 每股作价约82.07港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2638150420","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638150420?lang=zh_cn&edition=full","pubTime":"2026-05-27 19:10","pubTimestamp":1779880225,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新资料显示，5月21日，贝莱德增持信达生物(01801)36.9453万股，每股作价82.0651港元，总金额约为3031.92万港元。增持后最新持股数目约为8728.09万股，最新持股比例为5.02%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1446733.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1201861249.SGD","LU2430703095.HKD","BK4535","HK0000165453.HKD","LU0208291251.USD","LU0980610538.SGD","BK4135","LU0772969993.USD","BK4585","IE00B64PRP62.GBP","BK4567","BLK","IE00BGHQF631.EUR","BK4534","LU1509826696.USD","LU1989771016.USD","LU1291159041.SGD","LU1670627923.USD","LU2097828474.EUR","LU2097828557.USD","LU2328871848.SGD","EWH","BK4588","LU1280957306.USD","LU2505996509.AUD","BK1161","LU1599440770.SGD","IE00BVYPNV92.GBP","LU2097828714.EUR","IE00B3QW5Z07.USD","LU0640476718.USD","LU1481011911.USD","LU2242644610.SGD","IE00BDGV0183.EUR","BK4504","IE00B42XCP33.USD","LU1366333091.USD","LU1969619763.USD","LU2430703251.USD","LU0070302665.USD","01801","LU0742537680.HKD","LU1670628061.USD","LU1481011671.HKD","LU0320765489.SGD","LU2097828631.EUR","LU1074936037.SGD","BK1583","LU2430703178.SGD","LU2488822045.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637438463","title":"信达生物：购买及认购摩根大通与瑞银投资票据合计6.9亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2637438463","media":"南方财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637438463?lang=zh_cn&edition=full","pubTime":"2026-05-22 22:47","pubTimestamp":1779461220,"startTime":"0","endTime":"0","summary":"南财智讯5月22日电，信达生物（01801.HK）发布须予披露交易公告，公司全资附属公司分别以2.8亿美元及1.3亿美元购买摩根大通票据I及票据II，并以2.8亿美元认购瑞银票据，合计投资金额达6.9亿美元。上述票据均为美元计价的可赎回零息票据，到期日介于2027年至2028年，内含收益率在4.05%至4.65%之间。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605223747073832.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0267386448.USD","LU0502904849.HKD","JPM","LU0345770993.USD","LU0820561818.USD","LU1969619763.USD","LU2505996681.GBP","IE00B1XK9C88.USD","LU2054465674.USD","LU2242649171.HKD","LU1064131342.USD","IE00BKVL7J92.USD","LU2430703095.HKD","LU1496350171.SGD","BK4582","LU0070302665.USD","JPO","LU1119994496.HKD","LU2242644610.SGD","LU2552382058.USD","LU0208291251.USD","LU0265550946.USD","BK4534","IE00BLSP4239.USD","JPMO","SG9999002224.SGD","IE0034235188.USD","LU2592432038.USD","PGF","IE00BDRTCR15.USD","LU2237443549.SGD","01801","LU0320765646.SGD","LU2097828805.USD","BK1589","BK1583","LU1244550221.USD","IE00BHPRN162.USD","LU2357305700.SGD","LU0203347892.USD","LU2357627491.SGD","LU2430703251.USD","SG9999002232.USD","LU2488822045.USD","LU0234572021.USD","LU1116320901.HKD","LU0211326755.USD","JPX","LU1974910355.USD","LU0170899867.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1114862836","title":"信达生物再投5亿美元票据提升现金回报，修正员工激励股份总量","url":"https://stock-news.laohu8.com/highlight/detail?id=1114862836","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1114862836?lang=zh_cn&edition=full","pubTime":"2026-05-22 22:46","pubTimestamp":1779461171,"startTime":"0","endTime":"0","summary":"信达生物披露，旗下港控公司近期完成两笔摩根大通结构性票据购买以及一笔瑞银票据认购，总金额合计5.1亿美元，资金全部来自内部资源，并计入财务报表中的投资项目。公告显示，信达生物在过去一年已先后购入三笔摩根大通票据，金额合计1.2亿美元，年化收益率介于4.08%—5.15%。截至公告日，所有票据均未被发行人提前赎回。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01801"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115388848","title":"异动解读｜信达生物盘中上涨3.09%，达伯舒联合疗法获批叠加新药密集落地","url":"https://stock-news.laohu8.com/highlight/detail?id=1115388848","media":"行情直击","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1115388848?lang=zh_cn&edition=full","pubTime":"2026-05-22 09:38","pubTimestamp":1779413921,"startTime":"0","endTime":"0","summary":"5月22日，信达生物盘中上涨3.09%，报84.3港元/股，成交额1.9亿港元。消息面上，信达生物近日迎来多项新药获批利好。5月21日，公司公告达伯舒与爱优特联合疗法获NMPA批准，用于治疗既往接受VEGFR-TKI治疗失败的局部晚期或转移性肾细胞癌患者。此外，5月20日公司自主研发的匹康奇拜单抗注射液（信美悦）亦获批上市，适应症为中重度斑块状银屑病，同日IBI3031正式启动首个甲状腺眼病I期临床研究。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01801"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198470954","title":"和黄医药与信达生物联合宣布：爱优特®（呋喹替尼）联合达伯舒®（信迪利单抗注射液）获NMPA批准用于治疗局部晚期或转移性肾细胞癌","url":"https://stock-news.laohu8.com/highlight/detail?id=1198470954","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1198470954?lang=zh_cn&edition=full","pubTime":"2026-05-21 18:02","pubTimestamp":1779357741,"startTime":"0","endTime":"0","summary":"和黄医药与信达生物今日共同发布公告，宣布其合作开发的联合疗法——爱优特®（呋喹替尼）与达伯舒®（信迪利单抗注射液）——已正式获得中国国家药品监督管理局的上市批准。该联合疗法获批用于治疗局部晚期或转移性肾细胞癌患者，为这一领域的临床治疗提供了新的重要选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","LU2097828714.EUR","HK0000165453.HKD","LU2097828805.USD","LU0455707207.USD","LU2097828631.EUR","LU2488822045.USD","01801","BK1587","BK1161","BK1583","LU2097828557.USD","BK1588","LU2242644610.SGD","BK1589","LU2328871848.SGD","LU1969619763.USD","00013","LU2097828474.EUR","LU0502904849.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637865503","title":"信达生物(01801)：达伯舒® 联合爱优特® 获中国国家药监局批准用于治疗晚期或转移性肾细胞癌患者","url":"https://stock-news.laohu8.com/highlight/detail?id=2637865503","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637865503?lang=zh_cn&edition=full","pubTime":"2026-05-21 16:56","pubTimestamp":1779353809,"startTime":"0","endTime":"0","summary":"智通财经APP讯，信达生物 公布，达伯舒 和爱优特 的联合疗法的新药上市申请获中国国家药品监督管理局批准，用于治疗既往接受血管内皮生长因子受体-酪氨酸激酶抑制剂治疗失败且一线未接受程序性死亡受体-1或程序性死亡配体-1抑制剂的局部晚期或转移性肾细胞癌患者。此项批准是基于FRUSICA-2研究的数据支持。此次获批对中国晚期肾细胞癌患者而言是一个重要的里程碑。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1444501.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"信达生物(01801)：达伯舒® 联合爱优特® 获中国国家药监局批准用于治疗晚期或转移性肾细胞癌患者","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2097828631.EUR","LU2488822045.USD","BK1161","LU2097828714.EUR","LU1969619763.USD","BK1589","LU2097828474.EUR","LU2242644610.SGD","BK1583","LU2328871848.SGD","LU2097828557.USD","HK0000165453.HKD","LU2097828805.USD","01801","LU0455707207.USD","LU0502904849.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637380754","title":"港股异动 | 信达生物(01801)反弹逾4% IBI3031完成临床登记 重磅布局TED精准治疗赛道","url":"https://stock-news.laohu8.com/highlight/detail?id=2637380754","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637380754?lang=zh_cn&edition=full","pubTime":"2026-05-21 14:54","pubTimestamp":1779346486,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，信达生物反弹逾4%，截至发稿，涨3.02%，报81.8港元，成交额7.35亿港元。消息面上，5月20日，药物临床试验登记与信息公示平台官网公示，信达生物正式登记一项I期临床研究，旨在评估IBI3031单次及多次给药在甲状腺眼病患者中的安全性、耐受性和药代动力学特征，这也是该药物启动的首个临床试验。作为全球首创的双靶点创新药物，IBI3031凭借差异化机制与更优给药潜力，有望突破现有治疗局限，为TED患者带来更高效、便捷的治疗新选择。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1444418.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","BK1161","LU1969619763.USD","LU2328871848.SGD","LU2097828557.USD","LU2488822045.USD","LU2097828474.EUR","LU2242644610.SGD","LU0455707207.USD","BK1583","HK0000165453.HKD","01801","LU0502904849.HKD","LU2097828631.EUR","BK4588","LU2097828714.EUR","BK1589","VXUS","LU2097828805.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637802670","title":"【券商聚焦】浙商证券维持信达生物(01801)“买入”评级 指国际化与商业化加速突破","url":"https://stock-news.laohu8.com/highlight/detail?id=2637802670","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637802670?lang=zh_cn&edition=full","pubTime":"2026-05-21 14:16","pubTimestamp":1779344216,"startTime":"0","endTime":"0","summary":"2026年第一季度产品收入超38亿元同比增超50%，印证双轮驱动策略成效。浙商证券预计2026-2028年公司收入分别为179.46、219.66和252.67亿元，归母净利润分别为27.79、37.06和45.38亿元，维持“买入”评级。风险提示包括临床数据或商业化失败、产品销售不及预期、政策风险及测算风险。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250106/ZDQ3YWRiNzU2MjI5OWUwYTllMmZlMTAyNzEyNzQzMTU2MQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/ZDQ3YWRiNzU2MjI5OWUwYTllMmZlMTAyNzEyNzQzMTU2MQ==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1981934","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["601878","01801"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132725750","title":"异动解读｜信达生物盘中上涨3.46%，新药匹康奇拜单抗获批叠加生物科技板块回暖","url":"https://stock-news.laohu8.com/highlight/detail?id=1132725750","media":"行情直击","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1132725750?lang=zh_cn&edition=full","pubTime":"2026-05-21 09:58","pubTimestamp":1779328683,"startTime":"0","endTime":"0","summary":"5月21日，信达生物盘中上涨3.46%，报81.65港元/股，成交额1.77亿港元。消息面上，信达生物于5月20日公告，其自主研发的匹康奇拜单抗注射液（信美悦®）获得NMPA批准上市，适应症为中重度斑块状银屑病成人患者，该产品为特异性结合IL-23p19亚基的创新抗体，多项临床研究已达成终点。新药获批有望进一步丰富公司非肿瘤产品管线。此外，生物科技板块今日整体回暖，康方生物涨6.35%、科伦博泰生物涨3.62%、荣昌生物涨3.26%，板块情绪修复对信达生物此前连续调整后的反弹形成支撑。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01801"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636893362","title":"信达生物遭Zieziula Gary Joseph减持约4.34万股 每股作价约87.84港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2636893362","media":"新浪港股","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636893362?lang=zh_cn&edition=full","pubTime":"2026-05-20 08:09","pubTimestamp":1779235740,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　香港联交所最新资料显示，5月14日，Zieziula Gary Joseph减持信达生物（01801）4.3431万股，每股作价87.8416港元，总金额约为381.5万港元。减持后最新持股数目约为46.97万股，最新持股比例为0.03%。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2026-05-20/doc-inhynvwq2771460.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","BK1583","LU0455707207.USD","LU2328871848.SGD","EWH","01801","BK1589","LU2097828474.EUR","LU2097828805.USD","LU2242644610.SGD","LU2488822045.USD","LU0502904849.HKD","LU2097828631.EUR","HK0000165453.HKD","LU1969619763.USD","LU2097828557.USD","LU2097828714.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636030884","title":"【券商聚焦】招银国际：AI有望改变创新药研发范式","url":"https://stock-news.laohu8.com/highlight/detail?id=2636030884","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636030884?lang=zh_cn&edition=full","pubTime":"2026-05-19 13:13","pubTimestamp":1779167581,"startTime":"0","endTime":"0","summary":"当前，监管框架持续完善，传统药企与AI原生公司加速合作，AI制药正处于从研发提效工具迈向创新药研发范式重构的转折期。AI重构药物研发全链条，早期效率红利已率先显现。传统创新药研发长期受困于高成本、长周期和低成功率，AI技术正在改变靶点发现、分子筛选与优化等关键环节的研发范式。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250109/MWU1MjY1NDI2Mjg5NDIzOQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MWU1MjY1NDI2Mjg5NDIzOQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1981743","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06978","LU0067412154.USD","IE00B031HY20.USD","LU1960683339.HKD","LU0572944931.SGD","06185","09926","LU0315179316.USD","LU1226287792.SGD","06160","BK1589","AGIX","01093","AIPO","02269","09995","LU0417516738.SGD","LU1719994722.HKD","01177","LU1152091168.USD","01801","LU1226288170.HKD","159992","IE00BPRC5H50.USD","BK1583","CHAT","SG9999002562.SGD","LU0072913022.USD","LU0456846285.SGD","02616","02142","LU0516422952.EUR","LU1993786604.SGD","LU1303224171.USD","09688","LU0561508036.HKD","01877","LU0456827905.SGD","LU0348827113.USD","LU1880383366.USD","LU0348767384.USD","ARTY","LU0140636845.USD","LU0634319403.HKD","BK1588","BK1161","LU1152091754.HKD","LU0856984785.SGD","LU0326950275.SGD","LU2097828631.EUR"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2636483820","title":"【券商聚焦】中信建投：创新药迎盈利兑现期 国内商业化与海外授权双轮驱动业绩增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2636483820","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636483820?lang=zh_cn&edition=full","pubTime":"2026-05-18 09:32","pubTimestamp":1779067963,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投证券研究指，2026年上半年医药行业触底回暖，创新药迎来盈利兑现期，国内商业化与海外授权双轮驱动业绩增长，多家企业扭亏。26Q1对外授权总额超600亿美元，ADC、双抗等前沿赛道交易持续火热。2026年ASCO年会94项中国研究中选口头报告，依沃西单抗登上全体大会，标志着中国创新药全球学术影响力迈上新台阶。国内支付端医保谈判与商保目录合力支持真创新。建议关注创新药国际化、边际改善等结构性机会。","market":"us","thumbnail":"https://static.szfiu.com/news/20250109/NjdhYmE3ZDczMTc4NjgyMDYzMDA3NjI=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/NjdhYmE3ZDczMTc4NjgyMDYzMDA3NjI=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1981512","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","LU1226287875.USD","LU1152091754.HKD","01177","02142","06160","601066","LU0039217434.USD","LU1242518931.SGD","LU1242518857.USD","LU1969619763.USD","LU0359202008.SGD","LU1688375341.USD","159992","01877","IE00B0JY6N72.USD","LU0979878070.USD","LU0417516738.SGD","LU2097828557.USD","LU0326950275.SGD","02616","IE00B5MMRT66.SGD","BK1141","LU0561508036.HKD","02269","LU2097828474.EUR","LU1303224171.USD","BK1588","LU2399975544.HKD","09926","LU0456827905.SGD","SG9999002562.SGD","IE00B543WZ88.USD","IE00BZ08YR35.GBP","LU0348827113.USD","LU0516422952.EUR","BK1574","LU0516423174.USD","LU1152091168.USD","IE00BZ08YT58.USD","01093","01801","06185","LU2097828631.EUR","06978","IE00BZ08YS42.EUR","LU1993786604.SGD","LU0588546209.SGD","09995","09688"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635771239","title":"港股午评|恒生指数早盘跌0.87%      机器人板块逆市大涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2635771239","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635771239?lang=zh_cn&edition=full","pubTime":"2026-05-15 12:00","pubTimestamp":1778817625,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，港股恒生指数跌0.87%，跌229点，报26159点；恒生科技指数跌1.26%。港股早盘成交1511亿港元。机器人产业进入量产博弈阶段。均胜电子涨6%，公司聚焦机器人核心部件以及相关总成方案。通用Token降价引爆市场需求，迅策垂类Token溢价及需求坚挺。阿里健康跌超6%，年度经调整净利同增19.3%，公司CFO发生变更。建滔积层板跌4.87%，中国巨石宣布扩产，花旗料短期或对公司造成负面市场情绪。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1442090.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02715","BK4585","BK1116","01801","600362","603986","00358","513600","02432","603127","06127","002747","BK1183","01208","01888","02833","00241","MCHmain","02692","03986","HHImain","HSI","BK4588","02591","600699","003021","00699","HSTECH","03317"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635775068","title":"港股异动 | 信达生物(01801)早盘跌超8% 创始人俞德超近期减持股份 套现约1.21亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2635775068","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635775068?lang=zh_cn&edition=full","pubTime":"2026-05-15 10:33","pubTimestamp":1778812380,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，信达生物早盘跌超8%，截至发稿，跌7.61%，报80.1港元，成交额8.45亿港元。消息面上，信达生物创始人、董事会主席兼CEO俞德超，于2026年5月11日减持135.3万股，每股均价89.362港元，套现约1.21亿港元。减持后，其持股比例降至7.49%，仍为第一大股东。中邮证券指出，信达生物在2025年首次实现利润指标的全面转正，标志着其商业模式已跑通，正式进入盈利时代。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1442061.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2097828557.USD","BK4588","LU2488822045.USD","LU2097828714.EUR","BK1583","LU2097828805.USD","BK1589","LU2328871848.SGD","BK4585","LU0502904849.HKD","HK0000165453.HKD","VXUS","LU1969619763.USD","LU2097828474.EUR","BK1161","01801","LU2097828631.EUR","LU0455707207.USD","LU2242644610.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104330176","title":"异动解读 | 生物科技板块普跌，资金流向科技股，信达生物盘中大跌5.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=1104330176","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1104330176?lang=zh_cn&edition=full","pubTime":"2026-05-15 09:36","pubTimestamp":1778809002,"startTime":"0","endTime":"0","summary":"信达生物今日盘中大跌5.07%，引起了市场的广泛关注。消息面上，生物科技板块今日整体承压，呈现普跌格局。市场分析指出，当前AI、芯片等科技板块占据交易主线，市场风格偏好明显向科技倾斜，导致资金从创新药等生物科技板块分流。此外，创新药板块短期受流动性分流影响，资金存在阶段性获利回吐压力，信达生物前一交易日上涨后，短线或面临技术性调整。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["01801"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634296521","title":"小摩：医保目录调整加速创新药商业化 首选信达生物(01801)等","url":"https://stock-news.laohu8.com/highlight/detail?id=2634296521","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634296521?lang=zh_cn&edition=full","pubTime":"2026-05-12 14:23","pubTimestamp":1778567022,"startTime":"0","endTime":"0","summary":"摩根大通重申对信达生物(01801)、科伦博泰生物-B(06990)、药明康德(02359) 及药明合联(02268)的正面看法，并将其列为行业首选股。","market":"fut","thumbnail":"https://img.zhitongcaijing.com/image/20260512/20260512142400_17997.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260512/20260512142400_17997.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1440606.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["LU0820562030.AUD","159992","IE00B1BXHZ80.USD","LU0070302665.USD","LU0320765646.SGD","BK4533","LU0345770993.USD","LU1551013425.SGD","BK4516","LU1974910355.USD","LU0234572021.USD","LU0320765489.SGD","JPMO","LU0211331839.USD","LU0820561818.USD","LU0683600562.USD","06978","BK4504","IE00BLSP4239.USD","LU2756315664.SGD","LU1548497426.USD","LU2456880835.USD","BK4588","LU1894683264.USD","LU2357627491.SGD","LU0455707207.USD","LU2264538146.SGD","LU0211326755.USD","BK4550","LU0868494617.USD","IE00BJTD4N35.SGD","LU2505996509.AUD","LU0345769631.USD","LU1064131342.USD","LU0976567544.SGD","LU0238689110.USD","LU2552382215.SGD","IE0034235303.USD","LU2417539215.USD","LU2054465674.USD","LU0170899867.USD","LU1244550221.USD","BK4534","JPO","01801","IE00B1XK9C88.USD","LU0502904849.HKD","SG9999002232.USD","IE00BFXG1179.USD","IE00B775SV38.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634015154","title":"花旗：中国医疗保健行业基本面持续改善 首选药明康德(02359)等","url":"https://stock-news.laohu8.com/highlight/detail?id=2634015154","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634015154?lang=zh_cn&edition=full","pubTime":"2026-05-11 16:54","pubTimestamp":1778489665,"startTime":"0","endTime":"0","summary":"创新正获得回报，授权交易预付款及里程碑付款带动盈利，创新药销售加速，而CXO订单量更创下历史新高。展望未来，该行预期将有一系列短期催化剂，包括ASCO 2026年数据发布、授权交易势头持续、4月14日药品价格改革后续、CXO指引可能上调，以及市场整合加速利好医疗科技、服务及药房领导者。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1440195.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01276","IE00B031HY20.USD","LU1008478684.HKD","LU2417539215.USD","01672","LU2360032135.SGD","LU1951186391.HKD","603259","02359","LU1226288253.USD","LU1023057109.AUD","01801","LU0979878070.USD","LU1719994722.HKD","LU2125154935.USD","LU0326950275.SGD","LU1506573853.SGD","LU1226287792.SGD","LU1997244956.HKD","IE0008369823.USD","LU2242644610.SGD","LU0359202008.SGD","BK1191","LU0307460666.USD","LU1242518857.USD","LU0203347892.USD","SG9999004220.SGD","LU0572944931.SGD","LU1366192091.USD","BK1141","01093","02269","LU2097828714.EUR","LU0072461881.USD","LU0516423174.USD","LU0098860793.USD","IE00BZ08YT58.USD","LU2045819591.USD","IE00B5MMRT66.SGD","LU2488822045.USD","LU0516422366.SGD","LU0455707207.USD","LU0980610538.SGD","LU0310800965.SGD","LU0314109678.HKD","LU1997245177.USD","BK1515","LU0315179316.USD","BK4504","LU0170899867.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.innoventbio.com","stockEarnings":[{"period":"1week","weight":-0.0057},{"period":"1month","weight":-0.0551},{"period":"3month","weight":-0.064},{"period":"6month","weight":-0.161},{"period":"1year","weight":0.3258},{"period":"ytd","weight":0.0354}],"compareEarnings":[{"period":"1week","weight":-0.0126},{"period":"1month","weight":-0.023},{"period":"3month","weight":-0.0399},{"period":"6month","weight":-0.0205},{"period":"1year","weight":0.0832},{"period":"ytd","weight":-0.0118}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"信达生物制药是一家主要从事研发、生产及销售治疗肿瘤、心血管及代谢（CVM）、自身免疫及眼科等重大疾病创新药物的投资控股公司。药物形式包括单克隆抗体、多特异性抗体、免疫细胞因子、抗体偶联药物（ADC）、细胞治疗及小分子药物等。该公司的主要产品包括达伯舒（信迪利单抗注射液）、达攸同（贝伐珠单抗注射液）、苏立信（阿达木单抗注射液）、达伯华（利妥昔单抗注射液）、达伯坦（佩米替尼片）等。该公司主要在中国国内和海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.041076},{"month":2,"riseRate":0.75,"avgChangeRate":0.110526},{"month":3,"riseRate":0.25,"avgChangeRate":-0.01934},{"month":4,"riseRate":0.75,"avgChangeRate":0.043223},{"month":5,"riseRate":0.375,"avgChangeRate":0.008626},{"month":6,"riseRate":0.714286,"avgChangeRate":0.139165},{"month":7,"riseRate":0.428571,"avgChangeRate":0.010056},{"month":8,"riseRate":0.714286,"avgChangeRate":0.000214},{"month":9,"riseRate":0.571429,"avgChangeRate":0.032182},{"month":10,"riseRate":0.285714,"avgChangeRate":-0.02286},{"month":11,"riseRate":0.625,"avgChangeRate":0.079172},{"month":12,"riseRate":0.375,"avgChangeRate":0.024026}],"exchange":"SEHK","name":"信达生物","nameEN":"INNOVENT BIO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"信达生物(01801)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供信达生物(01801)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"信达生物,01801,信达生物股票,信达生物股票老虎,信达生物股票老虎国际,信达生物行情,信达生物股票行情,信达生物股价,信达生物股市,信达生物股票价格,信达生物股票交易,信达生物股票购买,信达生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"信达生物(01801)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供信达生物(01801)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}